The purpose of the study is the prospective and standardized data collection of patients treated with ion therapy at MedAustron.
During and up to 10 years after radiation therapy data regarding tumor control and treatment response as well as acute and late toxicities will be collected at regular time intervals. Additionally quality of life and sociodemographic status will be assessed in all study patients and neurocognitive assessment will be performed in patients undergoing ion radiation of the brain.
Study Type
OBSERVATIONAL
Enrollment
2,800
EBG MedAustron GmbH
Wiener Neustadt, Lower Austria, Austria
RECRUITINGTherapy response
Therapy Response according to RECIST Version 1.1
Time frame: 10 years
Overall survival
Time frame: 10 years
Progression-free survival
Time frame: 10 years
Local progression-free survival
Time frame: 10 years
Cause-specific survival
Time frame: 10 years
Toxicity according to NCI CTCAE
Acute/late toxicity according to CTCAEv4.03, June 14,2010
Time frame: 10 years
EORTC-QLQ-C30
Patient-reported quality of life
Time frame: Through study completion, at 3, 5, and 10 years
EORTC-QLQ-BN20
Patient-reported quality of life for brain cancer patients
Time frame: Through study completion, at 3, 5, and 10 years
EORTC-QLQ-PR25
Patient-reported quality of life for prostate cancer patients
Time frame: Through study completion, at 3, 5, and 10 years
Neurocognitive test battery
Change in cognition from baseline to endpoint as measured by standardized subtests of test battery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Through study completion, at 3, 5, and 10 years